Loading...
Loading...
Dendreon Corporation
DNDN today announced revenue for the fourth
quarter ended December 31, 2011, reporting gross product revenue of
approximately $82 million. This represents approximately 25% growth over the
third quarter ended September 30, 2011, and approximately 230% growth compared
to the fourth quarter ended December 31, 2010. In addition, Dendreon reported
full-year gross revenues from PROVENGE® (sipuleucel-T) sales of approximately
$228 million.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in